DK1251848T3 - Gyraseinhibitorer og anvendelse deraf - Google Patents

Gyraseinhibitorer og anvendelse deraf

Info

Publication number
DK1251848T3
DK1251848T3 DK01903077T DK01903077T DK1251848T3 DK 1251848 T3 DK1251848 T3 DK 1251848T3 DK 01903077 T DK01903077 T DK 01903077T DK 01903077 T DK01903077 T DK 01903077T DK 1251848 T3 DK1251848 T3 DK 1251848T3
Authority
DK
Denmark
Prior art keywords
gyrase inhibitors
gyrase
inhibitors
Prior art date
Application number
DK01903077T
Other languages
English (en)
Inventor
Steven Ronkin
Paul Charifson
Dean Stamos
Michael Badia
Anne-Laure Grillot
Martin Trudeau
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK1251848T3 publication Critical patent/DK1251848T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01903077T 2000-01-18 2001-01-16 Gyraseinhibitorer og anvendelse deraf DK1251848T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17667100P 2000-01-18 2000-01-18
US25433100P 2000-12-08 2000-12-08
EP01903077A EP1251848B1 (en) 2000-01-18 2001-01-16 Gyrase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK1251848T3 true DK1251848T3 (da) 2004-10-18

Family

ID=26872470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01903077T DK1251848T3 (da) 2000-01-18 2001-01-16 Gyraseinhibitorer og anvendelse deraf

Country Status (23)

Country Link
US (2) US6608087B1 (da)
EP (1) EP1251848B1 (da)
JP (1) JP2003520233A (da)
CN (1) CN1230166C (da)
AR (1) AR027518A1 (da)
AT (1) ATE269701T1 (da)
AU (1) AU782883B2 (da)
BR (1) BR0107713A (da)
CA (1) CA2397686A1 (da)
CO (1) CO5261612A1 (da)
DE (1) DE60103974T2 (da)
DK (1) DK1251848T3 (da)
EA (1) EA005680B1 (da)
ES (1) ES2222336T3 (da)
HK (1) HK1053984B (da)
MX (1) MXPA02007134A (da)
MY (1) MY133572A (da)
NZ (1) NZ520628A (da)
PT (1) PT1251848E (da)
SI (1) SI1251848T1 (da)
TR (1) TR200401735T4 (da)
TW (1) TWI287449B (da)
WO (1) WO2001052845A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256418A1 (en) * 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2003015776A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
EP1819721A1 (en) * 2004-11-19 2007-08-22 Plant Bioscience Limited Microcin b17 analogs and methods for their preparation and use
NZ561613A (en) 2005-02-18 2010-12-24 Astrazeneca Ab Antibacterial piperidine derivatives
CA2642264A1 (en) * 2006-02-13 2007-08-30 Trustees Of Boston University Reca inhibitors with antibiotic activity, compositions and methods of use
WO2007149989A2 (en) 2006-06-21 2007-12-27 Cook Incorporated Fistula grafts and related methods and systems useful for treating gastrointestinal fistulae
WO2008019292A2 (en) * 2006-08-04 2008-02-14 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
JPWO2010007943A1 (ja) * 2008-07-17 2012-01-05 旭化成ファーマ株式会社 含窒素複素環化合物
BRPI0919004A2 (pt) * 2008-09-22 2019-09-24 Cayman Chem Co composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
UY32856A (es) 2009-08-26 2011-03-31 Astrazeneca Ab Derivados heterocíclicos de urea y métodos de uso de los mismos
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012051410A2 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102911173A (zh) * 2012-11-08 2013-02-06 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP3102203A2 (en) 2014-02-03 2016-12-14 Spero Gyrase, Inc. Antibacterial combinations comprising polymyxin
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
US20210070747A1 (en) 2017-03-24 2021-03-11 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
WO2018213185A1 (en) 2017-05-17 2018-11-22 Drexel University Rela inhibitors for biofilm disruption
US12258342B2 (en) 2018-09-03 2025-03-25 Univerza V Ljubljani Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP4263503A1 (en) 2020-12-17 2023-10-25 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
NL2033609B1 (en) * 2022-11-24 2024-05-30 Innes John Centre DNA Gyrase Inhibitors
WO2024145662A1 (en) * 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
EP4663242A1 (en) * 2024-06-11 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Targeting the energy coupling factor (ecf) transporters as novel antimicrobial target

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
AU711128C (en) * 1996-05-09 2002-11-07 Sankyo Company Limited Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient

Also Published As

Publication number Publication date
HK1053984B (zh) 2006-07-28
JP2003520233A (ja) 2003-07-02
DE60103974D1 (de) 2004-07-29
MXPA02007134A (es) 2003-03-27
CN1230166C (zh) 2005-12-07
SI1251848T1 (en) 2004-12-31
TWI287449B (en) 2007-10-01
CA2397686A1 (en) 2001-07-26
PT1251848E (pt) 2004-10-29
DE60103974T2 (de) 2005-06-30
CN1400898A (zh) 2003-03-05
AU3094001A (en) 2001-07-31
ES2222336T3 (es) 2005-02-01
US20040024030A1 (en) 2004-02-05
EA005680B1 (ru) 2005-04-28
TR200401735T4 (tr) 2004-08-23
AR027518A1 (es) 2003-04-02
BR0107713A (pt) 2002-11-19
MY133572A (en) 2007-11-30
WO2001052845A1 (en) 2001-07-26
ATE269701T1 (de) 2004-07-15
EP1251848B1 (en) 2004-06-23
CO5261612A1 (es) 2003-03-31
US6930116B2 (en) 2005-08-16
HK1053984A1 (en) 2003-11-14
AU782883B2 (en) 2005-09-08
EP1251848A1 (en) 2002-10-30
EA200200769A1 (ru) 2002-12-26
US6608087B1 (en) 2003-08-19
NZ520628A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
NO20022656D0 (no) Caspaseinhibitorer og anvendelse derav
DK1268425T3 (da) Carbamatcaspaseinhibitorer og anvendelse deraf
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20024355D0 (no) Nukleosidforbindelser og anvendelser derav
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
NO20024709D0 (no) Borefluider og anvendelse derav
IS6822A (is) Imidazól- og bezimidazól kaspasatálmar og notkun þeirra
DK1322597T3 (da) Fremgangsmåde og intermediære
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
PT1339695E (pt) Inibidores da farnesiltransferase
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter